Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Perspective Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Perspective Therapeutics’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:34 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-342512
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Grant revenue | $81 | $290 | $157 | $632 |
| Operating expenses: | ||||
| Research and development | 21,544 | 16,620 | 42,916 | 30,952 |
| General and administrative | 7,795 | 7,709 | 14,780 | 15,551 |
| Total operating expenses | 29,339 | 24,329 | 57,696 | 46,503 |
| Operating loss | (29,258) | (24,039) | (57,539) | (45,871) |
| Non-operating income (expense): | ||||
| Interest income | 2,347 | 2,159 | 4,544 | 4,543 |
ITEM 1 - FINANCIAL STATEMENTS
FAQ
- What is Perspective Therapeutics's G&A?
- Perspective Therapeutics (CATX) reported G&A of $7.8M in Q2 2026.
- How has Perspective Therapeutics's G&A changed year-over-year?
- Perspective Therapeutics's G&A increased by 1.1% year-over-year, from $7.71M to $7.8M.
- What is the long-term trend for Perspective Therapeutics's G&A?
- Over 4 years (2021 to 2025), Perspective Therapeutics's G&A has grown at a 59.3% compound annual growth rate (CAGR), from $4.69M to $30.23M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Perspective Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude